4 documents found, page 1 of 1
Short and long-term clinical impact of transcatheter aortic valve implantation ...
Guerreiro, C; Ferreira, PC; Teles, RC; Braga, P; Canas da Silva, P; Patrício, L; Silva, JC; Baptista, J; de Sousa Almeida, M; Gama Ribeiro, V; Silva, BIntroduction: The Portuguese National Registry of Transcatheter Aortic Valve Implantation records prospectively the characteristics and outcomes of transcatheter aortic valve implantation (TAVI) procedures in Portugal. Objectives: To assess the 30-day and one-year outcomes of TAVI procedures in Portugal. Methods: We compared TAVI results according to the principal access used (transfemoral (TF) vs. non-transfem...
Short and Long-Term Clinical Impact of Transcatheter Aortic Valve Implantation ...
Guerreiro, C; Carrilho Ferreira, P; Campante Teles, R; Braga, P; Canas da Silva, P; Patrício, L; Silva, JC; Baptista, J; Sousa Almeida, MIntroduction: The Portuguese National Registry of Transcatheter Aortic Valve Implantation records prospectively the characteristics and outcomes of transcatheter aortic valve implantation (TAVI) procedures in Portugal. Objectives: To assess the 30-day and one-year outcomes of TAVI procedures in Portugal. Methods: We compared TAVI results according to the principal access used (transfemoral (TF) vs. non-transfem...
Use of drug-eluting vs. bare-metal stents after an acute coronary syndrome in P...
Barros, V; Pereira, M; Araújo, C; Braga, P; Azevedo, AINTRODUCTION AND OBJECTIVES: The interventional cardiologist chooses a specific stent type based on the risk-benefit profile for each case. In general, drug-eluting stents should be considered in all clinical conditions, except if there are concerns or contraindications for prolonged dual antiplatelet therapy. The aim of this work was to describe the use of bare-metal vs. drug-eluting stents in patients undergo...
Análise económica do rituximab, em associação com ciclofosfamida, vincristina e...
Braga, P; Carvalho, S; Gomes, M; Guerra, L; Lúcio, P; Marques, H; Negreiro, F; Pereira, C; Silva, C; Teixeira, AOBJECTIVE: Evaluate costs and benefits of rituximab in combination with cyclophosphamide/vincristine/prednisolone chemotherapy regimen (R-CVP), in previously untreated patients with indolent non-Hodgkin lymphoma (NHL), compared to CVP alone from a Portuguese National Health System (NHS) perspective. METHODS: Cost-effectiveness (Life Years Gained--LYG) and cost-utility analysis (Quality Adjusted Life Years--QALY...